Connect with us

Life Sciences

Cognosos Triples Revenue in 2022; Raises $25 Million to Solidify Its Leadership Position in Asset Visibility and Intelligence

Cognosos announced it has raised a growth round from Riverwood Capital with an initial primary investment of $25 million to solidify its position as the…

Published

on

This article was originally published by AITHORITY
Cognosos Triples Revenue in 2022; Raises $25 Million to Solidify Its Leadership Position in Asset Visibility and Intelligence

Cognosos announced it has raised a growth round from Riverwood Capital with an initial primary investment of $25 million to solidify its position as the leader of intelligent asset tracking. Many of the world’s most recognizable brands–including the largest automobile manufacturers and healthcare providers–use Cognosos’ real-time location services (RTLS) and process optimization software platform to track their assets’ movements, improve their operational visibility, and maximize productivity safely.

AiThority Interview : AiThority Interview with Shaun McGirr, Field CDO at Dataiku

Healthcare and automotive manufacturing are among the top industries driving the US economy, and both are experiencing margin pressure due mainly to higher costs for labor and supplies. To address this, businesses in these critical categories are turning to Cognosos’ RTLS technology and process optimization software to improve asset visibility and garner insights that drive greater efficiency, improving customer and employee experiences alike. In 2022 alone, Cognosos technology seamlessly tracked over 37 million asset movements for its customers (with applications in finished vehicle logistics, yard management and hospital asset tracking/orchestration). Further, Cognosos’ unique wireless networking technology and AI-powered location engine drastically reduce deployment timelines enabling enterprises to implement highly accurate, real-time asset visibility in a fraction of the time required for legacy RTLS solutions.

This new investment will be used to expedite growth and momentum across all parts of the business. Cognosos will continue to recruit and hire top talent in every department, while significantly expanding its go-to-market efforts in automotive, healthcare and logistics categories as well as new segments. In addition, funds will be used to accelerate the development and deployment of platform enhancements and complementary offerings that will provide customers with even deeper operational insights that can be used to meet their ongoing efficiency goals. Riverwood Capital’s Joe De Pinho and Eric Ma will join the Cognosos Board of Directors.

“Cognosos’ proprietary technology and AI-powered location software platform is allowing customers to take an entirely new approach to asset tracking and process optimization, allowing them to do more with less and make smarter, faster, and better business decisions,” said Francisco Alvarez-Demalde, Co-Founder and Managing Partner, Riverwood Capital. “We are impressed with the Cognosos team and unique technology and are excited to partner with them on the next phase of growth. The Company’s offering has a superior total cost of ownership and simpler deployment while maintaining industry-leading accuracy. Logistics and processes’ optimization are taken to a new level, compared with what is available to enterprises today,” he added.

Read More InterviewAiThority Interview with Mario Ciabarra, Founder and CEO of Quantum Metric

Cognosos is already working with some of the biggest organizations in healthcare and manufacturing and is seeing demand for its unique technology and software platform with new customers at a record pace. The company’s hardware, artificial intelligence-powered software and analytics solution deliver highly accurate asset-tracking capabilities without the need for costly infrastructure, a significant departure from legacy products that are hardware-centric, less reliable and require frequent maintenance.

“Business leaders can’t afford to take hits to their bottom line just because they don’t know where things are, but historically the large total cost of ownership has made the investment in an RTLS solution unfeasible,” said Braxton Jarratt, CEO of Cognosos. “Our lightweight architecture and AI-powered location engine are game-changers. By drastically reducing costs and installation timelines, RTLS becomes a very attractive investment. With our technology, customers are transforming and optimizing their operations with a greater level of insights and seeing meaningful savings and efficiency while they do it.”

Cognosos’ patented approach to RTLS combines Bluetooth Low Energy with AI and proprietary long-range wireless networking technology to achieve breakthroughs in cost, performance and accuracy. The result: an ultra-lightweight footprint with minimal infrastructure that enables high-confidence asset location accuracy, and actionable insights that produce a measurable, hard-dollar, financial return.

 Latest Interview Insights : AiThority Interview with Jessica Stafford, SVP of Consumer Solutions at Cox Automotive

 [To share your insights with us, please write to sghosh@martechseries.com] 

The post Cognosos Triples Revenue in 2022; Raises $25 Million to Solidify Its Leadership Position in Asset Visibility and Intelligence appeared first on AiThority.





artificial intelligence

Markets

Wittiest stocks:: Avalo Therapeutics Inc (NASDAQ:AVTX 0.00%), Nokia Corp ADR (NYSE:NOK 0.90%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Spellbinding stocks: LumiraDx Limited (NASDAQ:LMDX 4.62%), Transocean Ltd (NYSE:RIG -2.67%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner

The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….

Continue Reading

Trending